152 related articles for article (PubMed ID: 33320972)
1. Upfront treatment with mTOR inhibitor everolimus in pediatric low-grade gliomas: A single-center experience.
Cacchione A; Lodi M; Carai A; Miele E; Tartaglia M; Megaro G; Del Baldo G; Alessi I; Colafati GS; Carboni A; Boccuto L; Diomedi Camassei F; Catanzaro G; Po A; Ferretti E; Pedace L; Pizzi S; Folgiero V; Pezzullo M; Corsetti T; Secco DE; Cefalo MG; Locatelli F; Mastronuzzi A
Int J Cancer; 2021 May; 148(10):2522-2534. PubMed ID: 33320972
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.
Ullrich NJ; Prabhu SP; Reddy AT; Fisher MJ; Packer R; Goldman S; Robison NJ; Gutmann DH; Viskochil DH; Allen JC; Korf B; Cantor A; Cutter G; Thomas C; Perentesis JP; Mizuno T; Vinks AA; Manley PE; Chi SN; Kieran MW
Neuro Oncol; 2020 Oct; 22(10):1527-1535. PubMed ID: 32236425
[TBL] [Abstract][Full Text] [Related]
3. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
[TBL] [Abstract][Full Text] [Related]
4. Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma.
Leclair NK; Lambert W; Roche K; Gillan E; Gell JJ; Lau CC; Wrubel G; Knopf J; Amin S; Anderson M; Martin JE; Bookland MJ; Hersh DS
Neurosurg Focus; 2022 Dec; 53(6):E15. PubMed ID: 36455272
[TBL] [Abstract][Full Text] [Related]
5. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
Wahl M; Chang SM; Phillips JJ; Molinaro AM; Costello JF; Mazor T; Alexandrescu S; Lupo JM; Nelson SJ; Berger M; Prados M; Taylor JW; Butowski N; Clarke JL; Haas-Kogan D
Cancer; 2017 Dec; 123(23):4631-4639. PubMed ID: 28759109
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Pediatric Low-Grade Gliomas.
Sait SF; Giantini-Larsen AM; Tringale KR; Souweidane MM; Karajannis MA
Curr Neurol Neurosci Rep; 2023 Apr; 23(4):185-199. PubMed ID: 36881254
[TBL] [Abstract][Full Text] [Related]
7. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
[TBL] [Abstract][Full Text] [Related]
8. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
[TBL] [Abstract][Full Text] [Related]
9. Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target.
Hütt-Cabezas M; Karajannis MA; Zagzag D; Shah S; Horkayne-Szakaly I; Rushing EJ; Cameron JD; Jain D; Eberhart CG; Raabe EH; Rodriguez FJ
Neuro Oncol; 2013 Dec; 15(12):1604-14. PubMed ID: 24203892
[TBL] [Abstract][Full Text] [Related]
10. Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment.
Tsai JW; Choi JJ; Ouaalam H; Murillo EA; Yeo KK; Vogelzang J; Sousa C; Woods JK; Ligon KL; Warfield SK; Bandopadhayay P; Cooney TM
Neurooncol Adv; 2023; 5(1):vdac182. PubMed ID: 36926246
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.
Poore B; Yuan M; Arnold A; Price A; Alt J; Rubens JA; Slusher BS; Eberhart CG; Raabe EH
Neuro Oncol; 2019 Feb; 21(2):252-263. PubMed ID: 30239952
[TBL] [Abstract][Full Text] [Related]
12. Overcoming resistance to single-agent therapy for oncogenic
Jain P; Silva A; Han HJ; Lang SS; Zhu Y; Boucher K; Smith TE; Vakil A; Diviney P; Choudhari N; Raman P; Busch CM; Delaney T; Yang X; Olow AK; Mueller S; Haas-Kogan D; Fox E; Storm PB; Resnick AC; Waanders AJ
Oncotarget; 2017 Oct; 8(49):84697-84713. PubMed ID: 29156677
[TBL] [Abstract][Full Text] [Related]
13. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetics and therapeutic targets of pediatric low-grade gliomas.
Tateishi K; Nakamura T; Yamamoto T
Brain Tumor Pathol; 2019 Apr; 36(2):74-83. PubMed ID: 30929113
[TBL] [Abstract][Full Text] [Related]
15. Early treatment of complex located pediatric low-grade gliomas using iodine-125 brachytherapy alone or in combination with microsurgery.
Kunz M; Nachbichler SB; Ertl L; Fesl G; Egensperger R; Niyazi M; Schmid I; Tonn JC; Peraud A; Kreth FW
Cancer Med; 2016 Mar; 5(3):442-53. PubMed ID: 26714663
[TBL] [Abstract][Full Text] [Related]
16. A Molecular Update and Review of Current Trials in Paediatric Low-Grade Gliomas.
Al-Jilaihawi S; Lowis S
Pediatr Neurosurg; 2023; 58(5):290-298. PubMed ID: 37604126
[TBL] [Abstract][Full Text] [Related]
17. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
18. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.
Buzzoni R; Pusceddu S; Bajetta E; De Braud F; Platania M; Iannacone C; Cantore M; Mambrini A; Bertolini A; Alabiso O; Ciarlo A; Turco C; Mazzaferro V
Ann Oncol; 2014 Aug; 25(8):1597-603. PubMed ID: 24827133
[TBL] [Abstract][Full Text] [Related]
19. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma.
Wright KD; Yao X; London WB; Kao PC; Gore L; Hunger S; Geyer R; Cohen KJ; Allen JC; Katzenstein HM; Smith A; Boklan J; Nazemi K; Trippett T; Karajannis M; Herzog C; Destefano J; Direnzo J; Pietrantonio J; Greenspan L; Cassidy D; Schissel D; Perentesis J; Basu M; Mizuno T; Vinks AA; Prabhu SP; Chi SN; Kieran MW
Pediatr Blood Cancer; 2021 Feb; 68(2):e28787. PubMed ID: 33140540
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
